The Hidden Link Between HIV and Cardiomyopathy: Unraveling HIV’s Impact on the Heart

For years, human immunodeficiency virus (HIV) was considered primarily an immunological threat. However, advancements in HIV treatment have dramatically increased life expectancy for those living with the virus, revealing a growing concern: an increased risk of cardiovascular disease, particularly cardiomyopathy. This review examines the complex relationship between HIV and cardiomyopathy, exploring the underlying mechanisms, clinical presentations, diagnostic approaches, and treatment strategies.

Understanding HIV-Associated Cardiomyopathy

Cardiomyopathy refers to diseases of the heart muscle that develop it harder for the heart to pump blood. In the context of HIV, cardiomyopathy isn’t a single condition but rather a spectrum of cardiac dysfunction. The prevalence of cardiac involvement in individuals with AIDS has been reported to range from 28% to 73% ¹. As HIV treatment improves and individuals live longer, the incidence of these cardiovascular complications is becoming increasingly apparent.

Pathogenesis: How HIV Impacts the Heart

The development of cardiomyopathy in people living with HIV is multifaceted. Several factors contribute to this increased risk:

• Direct Viral Effects: HIV can directly infect cardiac cells, leading to inflammation, and damage.
• Inflammation: Chronic immune activation, a hallmark of HIV infection, contributes to systemic inflammation, which can affect the heart.
• Co-infections: Individuals with HIV are more susceptible to other infections that can impact cardiac health.
• Antiretroviral Therapy (ART): While life-saving, some ART medications have been linked to cardiac side effects, though newer regimens are generally better tolerated.
• Traditional Cardiovascular Risk Factors: People with HIV often have a higher prevalence of traditional risk factors like hypertension, hyperlipidemia, and diabetes.

Recent advances in cardiac imaging and immunology are deepening our understanding of the specific mechanisms driving HIV-associated cardiovascular disease (CVD) ².

Clinical Manifestations

HIV-associated cardiomyopathy can manifest in various ways, including:

• Dilated Cardiomyopathy: The heart chambers enlarge, reducing the heart’s ability to pump effectively.
• Restrictive Cardiomyopathy: The heart muscle becomes stiff, hindering its ability to fill with blood.
• Hypertrophic Cardiomyopathy: The heart muscle thickens, making it harder for the heart to relax and fill with blood.
• Heart Failure: A condition where the heart can’t pump enough blood to meet the body’s needs.

Symptoms can range from shortness of breath and fatigue to swelling in the legs and ankles, and irregular heartbeat.

Diagnosis

Diagnosing HIV-associated cardiomyopathy requires a comprehensive evaluation, including:

• Echocardiogram: An ultrasound of the heart to assess its structure and function.
• Electrocardiogram (ECG): Measures the electrical activity of the heart.
• Cardiac Magnetic Resonance Imaging (MRI): Provides detailed images of the heart muscle.
• Biomarkers: Blood tests to measure levels of cardiac enzymes and hormones.

Treatment Strategies

Management of HIV-associated cardiomyopathy involves a multi-pronged approach:

• Antiretroviral Therapy: Suppressing HIV replication is crucial to reduce inflammation and viral load.
• Management of Cardiovascular Risk Factors: Controlling blood pressure, cholesterol, and diabetes.
• Heart Failure Medications: Including ACE inhibitors, beta-blockers, and diuretics, as appropriate.
• Lifestyle Modifications: Including a heart-healthy diet, regular exercise, and smoking cessation.

This review significantly enhances the understanding of HIV-associated cardiomyopathy, providing valuable insights for clinicians and researchers ³.

The Evolving Landscape of HIV and Cardiovascular Health

As individuals with HIV continue to live longer, healthier lives thanks to advancements in treatment, the focus is shifting towards understanding and addressing the long-term cardiovascular complications of the virus. Improved life expectancy has changed the paradigm regarding the long-term impact of HIV on cardiovascular health ⁴. Continued research and proactive cardiac monitoring are essential to improve outcomes for this vulnerable population.